Sera prognostics CIO Harrison Gardner sells shares value $119,678

In a current submitting with the Securities and Alternate Fee, Sera Prognostics, Inc. (NASDAQ:SERA), an organization with a market capitalization of $216 million, reported that its Chief Info Officer, Harrison Robert Gardner, executed a collection of inventory gross sales. The timing is notable as InvestingPro information exhibits the inventory has declined over 23% up to now week. On January 10 and January 13, 2025, Gardner bought a complete of 16,473 shares of Class A Frequent Inventory throughout three transactions. The gross sales have been performed at costs starting from $6.47 to $8.01 per share, amounting to a complete transaction worth of $119,678. Based on InvestingPro evaluation, the corporate maintains a powerful steadiness sheet with more money than debt and a wholesome present ratio of two.11, indicating stable short-term monetary stability.

The transactions have been carried out below a Rule 10b5-1 buying and selling plan, which Gardner adopted on Might 14, 2024. Following these gross sales, Gardner retains possession of 114,573 shares of Sera Prognostics. For deeper insights into SERA’s valuation and eight further key funding suggestions, try the excellent evaluation accessible on InvestingPro.

In different current information, Sera Prognostics, a medical laboratory providers firm, introduced the Society for Maternal Fetal Drugs (SMFM) has printed an summary with topline outcomes from the PRIME examine. The examine’s findings, specializing in bettering neonatal outcomes by prematurity danger evaluation mixed with scientific interventions, are set to be introduced later this month. Following this, the corporate plans to host a convention name and stay audio webcast for a extra in-depth dialogue of the examine’s outcomes.

By way of financials, Sera Prognostics just lately reported a lower in web income to $29,000 from $42,000 in the identical quarter of the earlier yr. Working bills rose by 8% to $8.9 million, and the web loss elevated by 10% to $7.9 million. Regardless of these figures, the corporate maintains a powerful money reserve of $74.3 million, projected to maintain operations into 2027.

In a bid to sort out rising preterm start charges within the U.S., the corporate is specializing in enhancing the adoption of its PreTRM check. CEO Evguenia Lindgardt underlined the importance of the forthcoming publication of the PRIME scientific examine leads to securing payer help and influencing scientific tips. These developments are a part of Sera Prognostics’ technique for business progress and sustaining stable money reserves within the coming years.

This text was generated with the help of AI and reviewed by an editor. For extra info see our T&C.